吡格列酮对2型糖尿病患者血管内皮细胞功能及胰岛素抵抗的影响

陈培红

吡格列酮对2型糖尿病患者血管内皮细胞功能及胰岛素抵抗的影响

陈培红

上海市奉贤区中心医院内分泌科上海 201400

基金项目: 中国高校医学期刊临床专项资金

详细信息

中图分类号: R587.1
计量
- 文章访问数: 210
- HTML全文浏览量: 72
- PDF下载量: 14
出版历程
- 发布日期: 2013-02-27

Influence of pioglitazone on insulin resistance and vascular endothelial cell function in type 2 diabetic patients

CHEN Peihong

摘要

摘要: 目的观察吡格列酮(PIO)治疗糖尿病患者血管内皮细胞功能的变化及其对胰岛素抵抗(IR)的影响.方法随机选取2型糖尿病伴糖耐量减低(IGT)患者60例为观察组,正常对照组30例.观察组患者用PI0 30 mg/d治疗4个月.治疗前后分别检测反应性充血肱动脉内径增加程度(FMD),含服硝酸甘油后的血管舒张幅度(NID)指标,计算胰岛素敏感指数(ISI)、组织葡萄糖摄取率(GDR)和胰岛素抵抗指数(HOMA-IR).结果 2型糖尿病糖耐量减低患者治疗前后比较,血糖指标(FBG、HbAlc、HOMA-IR)水平降低,ISI值升高；吡格列酮治疗组与常规治疗组比较,血清脂联素无差异(P＞0.05)；与正常对照组比较,FMD显著降低,NID无显著性变化；治疗组FMD较治疗前升高,而NID值治疗前后无显著性变化.结论吡格列酮能增加2型糖尿病并发心血管病患者血清脂联素水平,改善IR.
- 2型糖尿病 /
- 心血管并发症 /
- 胰岛素抵抗 /
- 吡格列酮

HTML全文

参考文献(13)

Harald Sourij, Robert Zweiker, Thomas C. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes [J]. Diabetes Care, 2006(5):1039.

金菊英, 余叶蓉, 喻红玲. 吡格列酮对伴糖耐量减低的代谢综合征患者血管内皮细胞功能的影响 [J]. 中国糖尿病杂志, 2007(9):531.doi: 10.3321/j.issn:1006-6187.2007.09.008.

Werner C, Kamani C H, Gensch C. The peroxisome proliferator activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance [J]. Diabetes, 2007, (10):2609.

DeFronzo R A, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes [J]. Diabetes Care, 2009, (Suppl 2):S157.

Holman R R, Haffner S M, McMurray J J. Effect of nateglinide on the incidence of diabetes and cardiovascular events [J]. New England Journal of Medicine, 2010, (16):1463.

Mazzone T, Meyer P M, Feinstein S B. Effect of pioglitazone compared with glimepiride on carotid intima-media thicktess in type 2 diabetes:a randomized trial [J]. Journal of the American Medical Association, 2006, (21):2572.

张婷. 盐酸吡格列酮对2型糖尿病患者血管内皮功能和高敏C反应蛋白的影响 [J]. 实用临床医药杂志, 2011, (13):29.doi: 10.3969/j.issn.1672-2353.2011.13.010.

朱启伟, 王浩, 张今尧. 吡格列酮对缺氧复氧心肌细胞损伤的保护作用及对蛋白激酶C表达的影响 [J]. 南方医科大学学报, 2011, (11):1819.doi: 44-1627/R.20111104.0931.002.

谭国据, 陈俏容, 林秋果. 门冬胰岛素联合吡格列酮治疗肝源性糖尿病的临床观察 [J]. 海南医学院学报, 2011(8):1057.doi: CNKI:46-1049/R.20110613.1457.005.

田亚强, 苏旭东, 赵家军. 吡格列酮对高脂饮食SD大鼠心功能的影响 [J]. 第三军医大学学报, 2011(1):65.

Nissen S E, Nicholls S J, Wolski K. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes:the periscope randomized controlled trial [J]. Journal of the American Medical Association, 2008, (13):1561.

DeFronzo R A. Bantins Lecture:From the triumvirate to the ominous octet:a new paradigm for the treatment of type 2 diabetes mellims [J]. Diabetes, 2009(4):773.

Lincoff A M, Wolski K, Nicholls S J. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus:a meta analysis of randomized trials [J]. Journal of the American Medical Association, 2007, (10):118.

施引文献

资源附件(0)

计量

文章访问数: 210
HTML全文浏览量: 72
PDF下载量: 14
被引次数: 0

吡格列酮对2型糖尿病患者血管内皮细胞功能及胰岛素抵抗的影响

计量

出版历程

Influence of pioglitazone on insulin resistance and vascular endothelial cell function in type 2 diabetic patients

计量

出版历程

目录